Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia

Drugs
M I Wilde, D McTavish

Abstract

Tamsulosin is the first subtype-selective (alpha IA) alpha 1 adrenoceptor antagonist with specificity for prostatic alpha 1 adrenoceptors (alpha 1A adrenoceptors are thought to be involved in prostatic smooth muscle contraction) to become available for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH). With tamsulosin, the incidence of adverse events commonly associated with alpha 1 adrenoceptor antagonism is similar to that with placebo (except for ejaculation disorders) and alfuzosin. The incidence of other adverse events is similar with tamsulosin and placebo. Furthermore, blood pressure and heart rate are not significantly affected by tamsulosin in patients with symptomatic BPH. In contrast, blood pressure is significantly reduced by alfuzosin compared with tamsulosin. Tamsulosin is available as a controlled release formulation suitable for once daily administration; dose titration is not required. The overall efficacy of this agent administered at a dosage of 0.1 to 0.4 mg/day in Japan, 0.4 mg/day in Europe and 0.4 to 0.8 mg/day in the US to patients with symptomatic BPH is greater than that of placebo was similar to that of alfuzosin or prazosin in the 2 available studies. Efficacy was primaril...Continue Reading

Citations

Mar 12, 1999·British Journal of Clinical Pharmacology·R F SchäfersM C Michel
Jun 26, 2001·British Journal of Clinical Pharmacology·M C MichelH Rübben
Aug 15, 2001·BJU International·K Harada, A Fujimura
Jun 23, 2005·The Journal of Pharmacy and Pharmacology·Min-Soo KimSung-Joo Hwang
Apr 1, 1997·Expert Opinion on Investigational Drugs·J P Hieble, R R Ruffolo
May 20, 1998·British Journal of Urology·A J Man In't VeldK van Loon
Feb 13, 1999·Journal of Clinical Pharmacology·W H Frishman, F Kotob
Jan 16, 2002·Drugs·Katherine A Lyseng-WilliamsonAntona J Wagstaff
May 23, 2002·Journal of Clinical Pharmacology·Sandeep DuttaMarleen Verlinden
Aug 2, 2006·Biological & Pharmaceutical Bulletin·Gopal GargShailendra Saraf
Mar 3, 2007·The Journal of Pharmacy and Pharmacology·Min-Soo KimSung-Joo Hwang
Nov 19, 2010·Journal of Medical Case Reports·Dileep Kumar, Fauzia Anis Khan
Oct 12, 2005·The Journal of Urology·Michael R RuggieriMichel A Pontari
May 15, 2002·The Journal of Pharmacy and Pharmacology·Sandeep DuttaMarleen Verlinden
May 16, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Alison BettsPaul Morgan
May 9, 2002·European Journal of Drug Metabolism and Pharmacokinetics·Sandeep DuttaMarleen Verlinden
Aug 31, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Vittorio CanalePaweł Zajdel
Nov 25, 2003·The Journal of Urology·Marco DellabellaGiovanni Muzzonigro
Apr 6, 2013·Current Medical Research and Opinion·Min-Gul KimJoo-Youn Cho
Dec 6, 2017·Therapeutic Advances in Drug Safety·Arunkumar D RanaChandrabhanu Rajkishor Tripathi
Dec 16, 2005·The Journal of Pharmacy and Pharmacology·Min-Soo KimSung-Joo Hwang
Nov 17, 2004·Mayo Clinic Proceedings·Debra A SchwinnPerinchery Narayan
Apr 17, 1998·European Journal of Pharmacology·M C Michel, M Goepel
Jul 9, 2010·Advances in Chronic Kidney Disease·Sarinya BoongirdMark L Unruh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.